Julien Chilloux
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Julien Chilloux has a total of 319 co-authors. Here are the top co-authors by number of shared publications:
- Marc-Emmanuel Dumas
Section of Biomolecular Medicine, Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
19 shared publications - Antonis Myridakis
Section of Biomolecular Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
11 shared publications - Lesley Hoyles
Nottingham Trent University
11 shared publications - Gilles Mithieux
Institut National de la Santé et de la Recherche Médicale, U1213, Lyon, F-69008, France
10 shared publications - Jeremy Kirk Nicholson
Imperial College London
9 shared publications M. Soty
7 shared publications
Latest Publications
- 31 March 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Rôle des mouvements membranaires dans la régulation de la production endogène de glucose
La production endogène de glucose est une fonction cruciale au maintien de l’homéostasie glucidique dont les 2 dernières étapes sont la production de glucose par la glucose-6-phosphatase (G6Pase) et la sortie du glucose hors de la cellule par le transporteur facilité GLUT2. Les mécanismes dépendants de mouvements membranaires régulant ces deux étapes ont été étudiés. La régulation de la G6Pase par l’AMPc dépend de mouvements membranaires. Cependant les mécanismes moléculaires de cette régulation restaient à caractériser. Nous avons étudié l’hypothèse d’une phosphorylation directe des sous-unités de la G6Pase par la PKA. La PKA est capable d’induire l’activité G6Pase. Cependant, aucune phosphorylation des sous-unités G6Pase n’a pu être mise en évidence par phosphorylation in vitro, mutations dirigées de sites potentiels de phosphorylation ou analyse par spectrométrie de masse. En absence de Glut2, le glucose produit de novo sort des hépatocytes par une voie dépendante de mouvements membranaires, dont le mécanisme moléculaire n’est pas caractérisé. Cette voie vésiculaire n’est pas impliquée dans la sortie du glucose glycogénolytique. À l’inverse, 50% du glucose néoglucogénique sort des hépatocytes par une voie vésiculaire, probablement dépendante de la cavéoline-1. Par microscopie confocale à fluorescence, nous avons montré que la G6Pase se déplace dans la cellule vers la membrane plasmique et co-localise avec une partie de la cavéoline1 cellulaire. Les vésicules composées de cavéoline-1 et contenant la G6Pase pourrait donc constituer un lien entre le réticulum endoplasmique, lieu de production du glucose et la membrane plasmique, lieu de libération du glucose
- 31 March 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Rôle des mouvements membranaires dans la régulation de la production endogène de glucose
La production endogène de glucose est une fonction cruciale au maintien de l’homéostasie glucidique dont les 2 dernières étapes sont la production de glucose par la glucose-6-phosphatase (G6Pase) et la sortie du glucose hors de la cellule par le transporteur facilité GLUT2. Les mécanismes dépendants de mouvements membranaires régulant ces deux étapes ont été étudiés. La régulation de la G6Pase par l’AMPc dépend de mouvements membranaires. Cependant les mécanismes moléculaires de cette régulation restaient à caractériser. Nous avons étudié l’hypothèse d’une phosphorylation directe des sous-unités de la G6Pase par la PKA. La PKA est capable d’induire l’activité G6Pase. Cependant, aucune phosphorylation des sous-unités G6Pase n’a pu être mise en évidence par phosphorylation in vitro, mutations dirigées de sites potentiels de phosphorylation ou analyse par spectrométrie de masse. En absence de Glut2, le glucose produit de novo sort des hépatocytes par une voie dépendante de mouvements membranaires, dont le mécanisme moléculaire n’est pas caractérisé. Cette voie vésiculaire n’est pas impliquée dans la sortie du glucose glycogénolytique. À l’inverse, 50% du glucose néoglucogénique sort des hépatocytes par une voie vésiculaire, probablement dépendante de la cavéoline-1. Par microscopie confocale à fluorescence, nous avons montré que la G6Pase se déplace dans la cellule vers la membrane plasmique et co-localise avec une partie de la cavéoline1 cellulaire. Les vésicules composées de cavéoline-1 et contenant la G6Pase pourrait donc constituer un lien entre le réticulum endoplasmique, lieu de production du glucose et la membrane plasmique, lieu de libération du glucose
- Open Access
- 5 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
A gut microbiome-kidney-heart axis predictive of future cardiovascular diseases
Cardiovascular diseases (CVD) remain a major global health challenge. Early markers of disease initiation and progression are urgently needed. We, and others, have previously shown changes in the gut microbiome in association with metabolic and CVD. Here, we demonstrate that gut microbiome-related changes can be detected in association with subclinical variations in heart and kidney function. Markers related to gut microbial metabolism of aromatic amino acids, phenylalanine and tyrosine, associate with circulating pro-atrial natriuretic peptide and estimated glomerular filtration rate in a metabolically healthy European population. Observational and genetic evidence further identify microbiome-related metabolites as mediators of this gut microbiome-kidney axis, with their baseline levels associating with incident CVD in an external Canadian population. Altogether, our work suggests that the gut microbiome interacts with the cardiorenal axis and participates in an interorgan crosstalk affecting host physiology and risk of CVD.
- 5 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessA gut microbiome-kidney-heart axis predictive of future cardiovascular diseases
Cardiovascular diseases (CVD) remain a major global health challenge. Early markers of disease initiation and progression are urgently needed. We, and others, have previously shown changes in the gut microbiome in association with metabolic and CVD. Here, we demonstrate that gut microbiome-related changes can be detected in association with subclinical variations in heart and kidney function. Markers related to gut microbial metabolism of aromatic amino acids, phenylalanine and tyrosine, associate with circulating pro-atrial natriuretic peptide and estimated glomerular filtration rate in a metabolically healthy European population. Observational and genetic evidence further identify microbiome-related metabolites as mediators of this gut microbiome-kidney axis, with their baseline levels associating with incident CVD in an external Canadian population. Altogether, our work suggests that the gut microbiome interacts with the cardiorenal axis and participates in an interorgan crosstalk affecting host physiology and risk of CVD.
- Open Access
- 8 December 2025
- Published by Springer Nature in Nature Metabolism
- Vol. 7 (12) , 2531-2547
Inhibition of IRAK4 by microbial trimethylamine blunts metabolic inflammation and ameliorates glycemic control
The global type 2 diabetes epidemic is a major health crisis. Although the microbiome has roles in the onset of insulin resistance (IR), low-grade inflammation and diabetes, the microbial compounds controlling these processes remain to be discovered. Here, we show that the microbial metabolite trimethylamine (TMA) decouples inflammation and IR from diet-induced obesity by inhibiting interleukin-1 receptor-associated kinase 4 (IRAK4), a central kinase in the Toll-like receptor pathway sensing danger signals. TMA blunts TLR4 signalling in primary human hepatocytes and peripheral blood monocytic cells and rescues mouse survival after lipopolysaccharide-induced septic shock. Genetic deletion and chemical inhibition of IRAK4 result in metabolic and immune improvements in high-fat diets. Remarkably, our results suggest that TMA—unlike its liver co-metabolite trimethylamine N -oxide, which is associated with cardiovascular disease—improves immune tone and glycemic control in diet-induced obesity. Altogether, this study supports the emerging role of the kinome in the microbial–mammalian chemical crosstalk.
- 8 December 2025
- Published by Springer Nature in Nature Metabolism
- Vol. 7 (12) , 2531-2547
Open AccessInhibition of IRAK4 by microbial trimethylamine blunts metabolic inflammation and ameliorates glycemic control
The global type 2 diabetes epidemic is a major health crisis. Although the microbiome has roles in the onset of insulin resistance (IR), low-grade inflammation and diabetes, the microbial compounds controlling these processes remain to be discovered. Here, we show that the microbial metabolite trimethylamine (TMA) decouples inflammation and IR from diet-induced obesity by inhibiting interleukin-1 receptor-associated kinase 4 (IRAK4), a central kinase in the Toll-like receptor pathway sensing danger signals. TMA blunts TLR4 signalling in primary human hepatocytes and peripheral blood monocytic cells and rescues mouse survival after lipopolysaccharide-induced septic shock. Genetic deletion and chemical inhibition of IRAK4 result in metabolic and immune improvements in high-fat diets. Remarkably, our results suggest that TMA—unlike its liver co-metabolite trimethylamine N -oxide, which is associated with cardiovascular disease—improves immune tone and glycemic control in diet-induced obesity. Altogether, this study supports the emerging role of the kinome in the microbial–mammalian chemical crosstalk.
- Open Access
- 8 September 2025
- Published by Springer Nature in Research Square
A gut microbiome-kidney-heart axis predictive of future cardiovascular diseases.
Cardiometabolic diseases (CMD) are on the rise globally with one billion people expected to suffer from obesity and 643 million from type 2 diabetes by 2030, of which one-third will likely develop chronic kidney disease and two-thirds will die from cardiovascular disease (CVD). However, the mechanistic and molecular drivers of the transition from health to disease remain elusive. Here, in 275 metabolically healthy individuals recruited to the MetaCardis study, we identify a gut microbiome-kidney-heart axis that is predictive of future cardiovascular events. This axis, as evidenced by the associations between gut microbial metabolism of phenylalanine and tyrosine with variations in both kidney functon(as measured by estimated glomerular filtration rate) and circulating pro-atrial natriuretic peptide concentration, shows a depletion pattern in metabolically unhealthy participants of the MetaCardis study (n = 1,602) indicating a loss of health-sustaining microbiome features with CMD progression. We then validate that microbial compounds from the phenylalanine and tyrosine pathways and their host co-metabolites act as mediators of the gut microbiome-kidney associations. Moreover, Mendelian Randomization analysis adds genetic evidence to suggest that the microbial mediator metabolites regulate host kidney function and vice versa. Finally, we demonstrate that plasma metabolites derived from the microbial metabolism of phenylalanine and tyrosine associate with incident CVD in the Canadian Longitudinal Study on Aging (n = 8,669). Collectively, our results depict the presence of a gut microbiome-kidney-heart axis in metabolically healthy individuals. Major aberrations of the gut microbiome as part of this axis throughout life may increase risk of CVD.
- 8 September 2025
- Published by Springer Nature in Research Square
Open AccessA gut microbiome-kidney-heart axis predictive of future cardiovascular diseases.
Cardiometabolic diseases (CMD) are on the rise globally with one billion people expected to suffer from obesity and 643 million from type 2 diabetes by 2030, of which one-third will likely develop chronic kidney disease and two-thirds will die from cardiovascular disease (CVD). However, the mechanistic and molecular drivers of the transition from health to disease remain elusive. Here, in 275 metabolically healthy individuals recruited to the MetaCardis study, we identify a gut microbiome-kidney-heart axis that is predictive of future cardiovascular events. This axis, as evidenced by the associations between gut microbial metabolism of phenylalanine and tyrosine with variations in both kidney functon(as measured by estimated glomerular filtration rate) and circulating pro-atrial natriuretic peptide concentration, shows a depletion pattern in metabolically unhealthy participants of the MetaCardis study (n = 1,602) indicating a loss of health-sustaining microbiome features with CMD progression. We then validate that microbial compounds from the phenylalanine and tyrosine pathways and their host co-metabolites act as mediators of the gut microbiome-kidney associations. Moreover, Mendelian Randomization analysis adds genetic evidence to suggest that the microbial mediator metabolites regulate host kidney function and vice versa. Finally, we demonstrate that plasma metabolites derived from the microbial metabolism of phenylalanine and tyrosine associate with incident CVD in the Canadian Longitudinal Study on Aging (n = 8,669). Collectively, our results depict the presence of a gut microbiome-kidney-heart axis in metabolically healthy individuals. Major aberrations of the gut microbiome as part of this axis throughout life may increase risk of CVD.
- Top Cited PapersOpen Access
- 20 September 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-18
Evidence of a causal and modifiable relationship between kidney function and circulating trimethylamine N-oxide
The host-microbiota co-metabolite trimethylamine N-oxide (TMAO) is linked to increased cardiovascular risk but how its circulating levels are regulated remains unclear. We applied “explainable” machine learning, univariate, multivariate and mediation analyses of fasting plasma TMAO concentration and a multitude of phenotypes in 1,741 adult Europeans of the MetaCardis study. Here we show that next to age, kidney function is the primary variable predicting circulating TMAO, with microbiota composition and diet playing minor, albeit significant, roles. Mediation analysis suggests a causal relationship between TMAO and kidney function that we corroborate in preclinical models where TMAO exposure increases kidney scarring. Consistent with our findings, patients receiving glucose-lowering drugs with reno-protective properties have significantly lower circulating TMAO when compared to propensity-score matched control individuals. Our analyses uncover a bidirectional relationship between kidney function and TMAO that can potentially be modified by reno-protective anti-diabetic drugs and suggest a clinically actionable intervention for decreasing TMAO-associated excess cardiovascular risk.
- 20 September 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-18
Top Cited PapersOpen AccessEvidence of a causal and modifiable relationship between kidney function and circulating trimethylamine N-oxide
The host-microbiota co-metabolite trimethylamine N-oxide (TMAO) is linked to increased cardiovascular risk but how its circulating levels are regulated remains unclear. We applied “explainable” machine learning, univariate, multivariate and mediation analyses of fasting plasma TMAO concentration and a multitude of phenotypes in 1,741 adult Europeans of the MetaCardis study. Here we show that next to age, kidney function is the primary variable predicting circulating TMAO, with microbiota composition and diet playing minor, albeit significant, roles. Mediation analysis suggests a causal relationship between TMAO and kidney function that we corroborate in preclinical models where TMAO exposure increases kidney scarring. Consistent with our findings, patients receiving glucose-lowering drugs with reno-protective properties have significantly lower circulating TMAO when compared to propensity-score matched control individuals. Our analyses uncover a bidirectional relationship between kidney function and TMAO that can potentially be modified by reno-protective anti-diabetic drugs and suggest a clinically actionable intervention for decreasing TMAO-associated excess cardiovascular risk.
- Top Cited PapersOpen Access
- 17 February 2022
- Published by Springer Nature in Nature Medicine
- Vol. 28 (2) , 303-314
Microbiome and metabolome features of the cardiometabolic disease spectrum
Previous microbiome and metabolome analyses exploring non-communicable diseases have paid scant attention to major confounders of study outcomes, such as common, pre-morbid and co-morbid conditions, or polypharmacy. Here, in the context of ischemic heart disease (IHD), we used a study design that recapitulates disease initiation, escalation and response to treatment over time, mirroring a longitudinal study that would otherwise be difficult to perform given the protracted nature of IHD pathogenesis. We recruited 1,241 middle-aged Europeans, including healthy individuals, individuals with dysmetabolic morbidities (obesity and type 2 diabetes) but lacking overt IHD diagnosis and individuals with IHD at three distinct clinical stages—acute coronary syndrome, chronic IHD and IHD with heart failure—and characterized their phenome, gut metagenome and serum and urine metabolome. We found that about 75% of microbiome and metabolome features that distinguish individuals with IHD from healthy individuals after adjustment for effects of medication and lifestyle are present in individuals exhibiting dysmetabolism, suggesting that major alterations of the gut microbiome and metabolome might begin long before clinical onset of IHD. We further categorized microbiome and metabolome signatures related to prodromal dysmetabolism, specific to IHD in general or to each of its three subtypes or related to escalation or de-escalation of IHD. Discriminant analysis based on specific IHD microbiome and metabolome features could better differentiate individuals with IHD from healthy individuals or metabolically matched individuals as compared to the conventional risk markers, pointing to a pathophysiological relevance of these features.
- 17 February 2022
- Published by Springer Nature in Nature Medicine
- Vol. 28 (2) , 303-314
Top Cited PapersOpen AccessMicrobiome and metabolome features of the cardiometabolic disease spectrum
Previous microbiome and metabolome analyses exploring non-communicable diseases have paid scant attention to major confounders of study outcomes, such as common, pre-morbid and co-morbid conditions, or polypharmacy. Here, in the context of ischemic heart disease (IHD), we used a study design that recapitulates disease initiation, escalation and response to treatment over time, mirroring a longitudinal study that would otherwise be difficult to perform given the protracted nature of IHD pathogenesis. We recruited 1,241 middle-aged Europeans, including healthy individuals, individuals with dysmetabolic morbidities (obesity and type 2 diabetes) but lacking overt IHD diagnosis and individuals with IHD at three distinct clinical stages—acute coronary syndrome, chronic IHD and IHD with heart failure—and characterized their phenome, gut metagenome and serum and urine metabolome. We found that about 75% of microbiome and metabolome features that distinguish individuals with IHD from healthy individuals after adjustment for effects of medication and lifestyle are present in individuals exhibiting dysmetabolism, suggesting that major alterations of the gut microbiome and metabolome might begin long before clinical onset of IHD. We further categorized microbiome and metabolome signatures related to prodromal dysmetabolism, specific to IHD in general or to each of its three subtypes or related to escalation or de-escalation of IHD. Discriminant analysis based on specific IHD microbiome and metabolome features could better differentiate individuals with IHD from healthy individuals or metabolically matched individuals as compared to the conventional risk markers, pointing to a pathophysiological relevance of these features.
- 8 December 2021
- Published by Springer Nature in Nature
- Vol. 600 (7889) , 500-505
Combinatorial, additive and dose-dependent drug–microbiome associations
During the transition from a healthy state to cardiometabolic disease, patients become heavily medicated, which leads to an increasingly aberrant gut microbiome and serum metabolome, and complicates biomarker discovery1,2,3,4,5. Here, through integrated multi-omics analyses of 2,173 European residents from the MetaCardis cohort, we show that the explanatory power of drugs for the variability in both host and gut microbiome features exceeds that of disease. We quantify inferred effects of single medications, their combinations as well as additive effects, and show that the latter shift the metabolome and microbiome towards a healthier state, exemplified in synergistic reduction in serum atherogenic lipoproteins by statins combined with aspirin, or enrichment of intestinal Roseburia by diuretic agents combined with beta-blockers. Several antibiotics exhibit a quantitative relationship between the number of courses prescribed and progression towards a microbiome state that is associated with the severity of cardiometabolic disease. We also report a relationship between cardiometabolic drug dosage, improvement in clinical markers and microbiome composition, supporting direct drug effects. Taken together, our computational framework and resulting resources enable the disentanglement of the effects of drugs and disease on host and microbiome features in multimedicated individuals. Furthermore, the robust signatures identified using our framework provide new hypotheses for drug–host–microbiome interactions in cardiometabolic disease.
- 8 December 2021
- Published by Springer Nature in Nature
- Vol. 600 (7889) , 500-505
Combinatorial, additive and dose-dependent drug–microbiome associations
During the transition from a healthy state to cardiometabolic disease, patients become heavily medicated, which leads to an increasingly aberrant gut microbiome and serum metabolome, and complicates biomarker discovery1,2,3,4,5. Here, through integrated multi-omics analyses of 2,173 European residents from the MetaCardis cohort, we show that the explanatory power of drugs for the variability in both host and gut microbiome features exceeds that of disease. We quantify inferred effects of single medications, their combinations as well as additive effects, and show that the latter shift the metabolome and microbiome towards a healthier state, exemplified in synergistic reduction in serum atherogenic lipoproteins by statins combined with aspirin, or enrichment of intestinal Roseburia by diuretic agents combined with beta-blockers. Several antibiotics exhibit a quantitative relationship between the number of courses prescribed and progression towards a microbiome state that is associated with the severity of cardiometabolic disease. We also report a relationship between cardiometabolic drug dosage, improvement in clinical markers and microbiome composition, supporting direct drug effects. Taken together, our computational framework and resulting resources enable the disentanglement of the effects of drugs and disease on host and microbiome features in multimedicated individuals. Furthermore, the robust signatures identified using our framework provide new hypotheses for drug–host–microbiome interactions in cardiometabolic disease.
- Open Access
A network-based data-mining approach to investigate indole-related microbiota-host co-metabolism
Motivation: Indoles have been shown to play a significant role in cardiometabolic disorders. While some individual bacterial species are known to produce indole-adducts, to our best knowledge no studies have made use of publicly available genome data to identify prokaryotes, specifically those associated with the human gut microbiota, contributing to the indole metabolic network. Results: Here, we propose a computational strategy, comprising the integration of KEGG and BLAST, to identify prokaryote-specific metabolic reactions relevant for the production of indoles, as well as to predict new members of the human gut microbiota potentially involved in these reactions. By identifying relevant prokaryotic species for further validation studies in vitro , this strategy represents a useful approach for those interrogating the metabolism of other gut-derived microbial metabolites relevant to human health. Availability: All R scripts and files (gut microbial dataset, FASTA protein sequences, BLASTP output files) are available from https://github.com/AndreaRMICL/Microbial_networks . Contact: ARM: andrea.rodriguez-martinez13@imperial.ac.uk ; LH: lesley.hoyles@ntu.ac.uk .
Open AccessA network-based data-mining approach to investigate indole-related microbiota-host co-metabolism
Motivation: Indoles have been shown to play a significant role in cardiometabolic disorders. While some individual bacterial species are known to produce indole-adducts, to our best knowledge no studies have made use of publicly available genome data to identify prokaryotes, specifically those associated with the human gut microbiota, contributing to the indole metabolic network. Results: Here, we propose a computational strategy, comprising the integration of KEGG and BLAST, to identify prokaryote-specific metabolic reactions relevant for the production of indoles, as well as to predict new members of the human gut microbiota potentially involved in these reactions. By identifying relevant prokaryotic species for further validation studies in vitro , this strategy represents a useful approach for those interrogating the metabolism of other gut-derived microbial metabolites relevant to human health. Availability: All R scripts and files (gut microbial dataset, FASTA protein sequences, BLASTP output files) are available from https://github.com/AndreaRMICL/Microbial_networks . Contact: ARM: andrea.rodriguez-martinez13@imperial.ac.uk ; LH: lesley.hoyles@ntu.ac.uk .
- Open Access
The Microbial Metabolite 4-Cresol Improves Glucose Homeostasis and Enhances β-Cell Function
SUMMARY: Gut microbiota changes are associated with increased risk of Type 2 diabetes (T2D) and obesity. Through serum metabolome profiling in patients with cardiometabolic disease (CMD) we identified significant inverse correlation between the microbial metabolite 4-cresol and T2D. Chronic administration of non toxic dose of 4-cresol in two complementary preclinical models of CMD reduced adiposity, glucose intolerance and liver triglycerides, and enhanced insulin secretion in vivo , which may be explained by markedly increased pancreas weight, augmented islet density and size, and enhanced vascularisation suggesting activated islet neogenesis. Incubation of isolated islets with 4-cresol enhanced insulin secretion, insulin content and cell proliferation. In both CMD models 4-cresol treatment in vivo was associated with altered expression of SIRT1 and the kinase DYRK1A, which may contribute to mediate its biological effects. Our findings identify 4-cresol as an effective regulator of β-cell function and T2D endophenotypes, which opens therapeutic perspectives in syndromes of insulin deficiency.
Open AccessThe Microbial Metabolite 4-Cresol Improves Glucose Homeostasis and Enhances β-Cell Function
SUMMARY: Gut microbiota changes are associated with increased risk of Type 2 diabetes (T2D) and obesity. Through serum metabolome profiling in patients with cardiometabolic disease (CMD) we identified significant inverse correlation between the microbial metabolite 4-cresol and T2D. Chronic administration of non toxic dose of 4-cresol in two complementary preclinical models of CMD reduced adiposity, glucose intolerance and liver triglycerides, and enhanced insulin secretion in vivo , which may be explained by markedly increased pancreas weight, augmented islet density and size, and enhanced vascularisation suggesting activated islet neogenesis. Incubation of isolated islets with 4-cresol enhanced insulin secretion, insulin content and cell proliferation. In both CMD models 4-cresol treatment in vivo was associated with altered expression of SIRT1 and the kinase DYRK1A, which may contribute to mediate its biological effects. Our findings identify 4-cresol as an effective regulator of β-cell function and T2D endophenotypes, which opens therapeutic perspectives in syndromes of insulin deficiency.
- 9 August 2018
- Published by Springer Nature in Nature Medicine
- Vol. 24 (10) , 1628
Publisher Correction: Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women
In the version of this article originally published, the received date was missing. It should have been listed as 2 January 2018. The error has been corrected in the HTML and PDF versions of this article.
- 9 August 2018
- Published by Springer Nature in Nature Medicine
- Vol. 24 (10) , 1628
Publisher Correction: Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women
In the version of this article originally published, the received date was missing. It should have been listed as 2 January 2018. The error has been corrected in the HTML and PDF versions of this article.